- Home
- KLRS vs NXN Comparison
KLRS vs NXN Comparison
Compare KLRS & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- NXN
- Stock Information
- Founded
- KLRS 2019
- NXN 1992
- Country
- KLRS United States
- NXN United States
- Employees
- KLRS N/A
- NXN N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- NXN Trusts Except Educational Religious and Charitable
- Sector
- KLRS Health Care
- NXN Finance
- Exchange
- KLRS Nasdaq
- NXN Nasdaq
- Market Cap
- KLRS 46.0M
- NXN 47.3M
- IPO Year
- KLRS N/A
- NXN N/A
- Fundamental
- Price
- KLRS $4.78
- NXN $12.14
- Analyst Decision
- KLRS Strong Buy
- NXN
- Analyst Count
- KLRS 3
- NXN 0
- Target Price
- KLRS $21.50
- NXN N/A
- AVG Volume (30 Days)
- KLRS 107.9K
- NXN 9.7K
- Earning Date
- KLRS 11-13-2025
- NXN 01-01-0001
- Dividend Yield
- KLRS N/A
- NXN 4.23%
- EPS Growth
- KLRS N/A
- NXN N/A
- EPS
- KLRS N/A
- NXN 0.24
- Revenue
- KLRS N/A
- NXN N/A
- Revenue This Year
- KLRS N/A
- NXN N/A
- Revenue Next Year
- KLRS N/A
- NXN N/A
- P/E Ratio
- KLRS N/A
- NXN $48.42
- Revenue Growth
- KLRS N/A
- NXN N/A
- 52 Week Low
- KLRS $2.14
- NXN $10.64
- 52 Week High
- KLRS $23.69
- NXN $12.45
- Technical
- Relative Strength Index (RSI)
- KLRS 47.17
- NXN 63.17
- Support Level
- KLRS $4.67
- NXN $12.00
- Resistance Level
- KLRS $5.10
- NXN $12.24
- Average True Range (ATR)
- KLRS 0.41
- NXN 0.10
- MACD
- KLRS -0.03
- NXN 0.02
- Stochastic Oscillator
- KLRS 39.41
- NXN 75.76
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.